Effects of patient-controlled analgesia with hydromorphone or sufentanil on postoperative pulmonary complications in patients undergoing thoracic surgery: a quasi-experimental study

Table 1 Demographic data and patients’ characteristics

	Group A (n = 68)	Group B (n = 68)	P-value
Age (yr)	51.03 ± 10.02	48.37 ± 11.09	0.144
Height (cm)	162.74 ± 7.35	163.83 ± 9.11	0.442
Gender (F/M)	29/39	27/41	0.727
Weight (kg)	61.35 ± 7.64	60.69 ± 8.08	0.621
Smoking index	197.94 ± 349.10	207.35 ± 281.83	0.863
Duration of surgery (min)	178.51 ± 75.22	179.69 ± 68.08	0.924
Total amount of sufentanil (μg)	62.97 ± 14.16	60.59 ± 13.86	0.323
Total amount of remifentanil (mg)	1.18 ± 0.60	1.29 ± 0.68	0.329
Type of surgery			1.000
Thoracoscopic	54	54
Open Esophagectomy	14	14
Total amount of fluid use (mL)	1559.85 ± 588.93	1538.53 ± 512.87	0.891
White cell count (10⁹/L)	6.00 ± 2.20	6.18 ± 2.21	0.643
Percentage of neutrophils (%)	61.81 ± 10.05	60.08 ± 10.67	0.340
PH	7.42 ± 0.05	7.43 ± 0.03	0.202
PO₂ (mmHg)	85.38 ± 11.15	84.45 ± 12.36	0.648
PCO₂ (mmHg)	40.63 ± 4.31	40.46 ± 3.52	0.808

Smoking index = the number of cigarettes smoker per day multiply by number of years of smoking. Total amount of fluid use = Fluid therapy during surgery (crystalloid and colloid). Data given as mean ± SD or number of patients

ISSN: 1471-2253